阿尔茨海默病患者血清中Apelin13和FKBP5的表达水平及临床意义

doi:10.11958/20220022

天津医药 ›› 2022, Vol. 50 ›› Issue (10): 1088-1092.doi: 10.11958/20220022

阿尔茨海默病患者血清中Apelin13和FKBP5的表达水平及临床意义

闫春晓¹(), 李培越²^,^△(), 郑启秘¹, 邹晓¹, 李建波³

1 达州职业技术学院护理系（邮编635000）
2 达州市中心医院老年科
3.达州职业技术学院附属医院老年科

收稿日期:2022-01-04 修回日期:2022-03-04 出版日期:2022-10-15 发布日期:2022-10-20
通讯作者: 李培越 E-mail:mcx5632541@163.com;2776237298@qq.com
作者简介:闫春晓（1984）,女,讲师,主要从事老年疾病方面研究。E-mail： mcx5632541@163.com

The serum expression level and clinical significance of Apelin13 and FKBP5 in patients with Alzheimer's disease

YAN Chunxiao¹(), LI Peiyue²^,^△(), ZHENG Qimi¹, ZOU Xiao¹, LI Jianbo³

1 Department of Nursing, Dazhou Vocational and Technical College, Dazhou 635000, China
2 Department of Geriatrics, Dazhou Central Hospital
3. Department of Geriatrics, the Affiliated Hospital of Dazhou Vocational and Technical College

Received:2022-01-04 Revised:2022-03-04 Published:2022-10-15 Online:2022-10-20
Contact: LI Peiyue E-mail:mcx5632541@163.com;2776237298@qq.com

闫春晓, 李培越, 郑启秘, 邹晓, 李建波. 阿尔茨海默病患者血清中Apelin13和FKBP5的表达水平及临床意义[J]. 天津医药, 2022, 50(10): 1088-1092.

YAN Chunxiao, LI Peiyue, ZHENG Qimi, ZOU Xiao, LI Jianbo. The serum expression level and clinical significance of Apelin13 and FKBP5 in patients with Alzheimer's disease[J]. Tianjin Medical Journal, 2022, 50(10): 1088-1092.

摘要/Abstract

摘要：

目的探究阿尔茨海默病（AD）患者血清中Apelin13和FK506结合蛋白51（FKBP5）的表达水平及意义。方法选取93例AD患者（AD组）,同时选取同年龄层体检的90例健康者（对照组）。比较2组血清Apelin13、FKBP5 mRNA水平差异。Pearson相关分析Apelin13、FKBP5 mRNA与简易精神状态量表（MMSE）评分的相关性。采用受试者工作特征（ROC）曲线评估Apelin13、FKBP5 mRNA对AD患者重度认知功能障碍的诊断价值。结果 AD组患者MMSE评分、血清Apelin13水平较对照组降低,而FKBP5 mRNA水平较对照组升高（均P<0.01）。轻、中及重度组AD患者血清中Apelin13水平依次降低,而FKBP5 mRNA水平依次升高（均P<0.05）。二元Logistic回归分析显示,较高的MMSE评分、Apelin13是AD发生的保护因素,而较高的FKBP5 mRNA是AD发生的危险因素（均P<0.05）。AD患者MMSE评分与血清FKBP5 mRNA水平呈负相关,而与Apelin13水平呈正相关（均P<0.05）。ROC曲线显示,Apelin13联合FKBP5 mRNA诊断重度认知功能障碍的曲线下面积（AUC）及95%CI[0.884（0.808~0.961）]明显高于单一Apelin13[0.776（0.673~0.879）]或FKBP5 mRNA[0.801（0.699~0.902）],其敏感度和特异度分别为81.25%和86.89%（均P<0.05）。结论 AD患者血清中Apelin13水平降低,而FKBP5 mRNA水平升高,Apelin13联合FKBP5 mRNA对AD患者重度认知功能障碍具有良好的诊断效能。

关键词: 阿尔茨海默病, 认知障碍, 他克莫司结合蛋白质类, ROC曲线, 早期诊断, Apelin13, FK506结合蛋白51

Abstract:

Objective To investigate the serum expression level and clinical significance of Apelin13 and FK506 binding protein 51 (FKBP5) in patients with Alzheimer's disease (AD). Methods A total of 93 AD patients were selected (the AD group), and 90 healthy subjects of the same age for physical examination were selected as the control group. The serum levels of Apelin13 and FKBP5 mRNA were compared between the groups. The correlation between Apelin13, FKBP5 mRNA and Mini-mental State Examination (MMSE) score was analyzed by Pearson correlation analysis. Receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of Apelin13 and FKBP5 mRNA for severe cognitive impairment in AD patients. Results The serum level of Apelin13 and MMSE scores were significantly lower in the AD group than those in the control group, while the level of FKBP5 mRNA was significantly higher in the AD group than that in the control group (P<0.01). The serum levels of Apelin13 decreased sequentially in patients with mild, moderate and severe AD, while levels of FKBP5 mRNA increased sequentially (all P<0.05). Binary Logistic regression analysis showed that higher MMSE score and Apelin13 were protective factors for AD, while higher FKBP5 mRNA was a risk factor for the development of AD (all P<0.05). MMSE score was negatively correlated with the serum level of FKBP5 mRNA and positively correlated with the level of Apelin13 in AD patients (all P<0.05). ROC curve showed that the AUC value [0.884 (0.808-0.961)] of Apelin13 combined with FKBP5 mRNA was significantly higher than that of Apelin13 or FKBP5 mRNA [0.776 (0.673-0.879) or 0.801 (0.699-0.902)], and the sensitivity and specificity of combined diagnosis were 81.25 and 86.89, respectively (all P<0.05). Conclusion The serum level of Apelin13 is decreased in AD patients, while FKBP5 mRNA is increased. Apelin13 combined with FKBP5 mRNA has good diagnostic efficacy for severe cognitive impairment in AD patients.

Key words: Alzheimer disease, cognition disorders, Tacrolimus binding proteins, ROC curve, early diagnosis, Apelin13, FK506 binding protein 51

中图分类号:

R742

图/表 5

参考文献 16

[1]	TEZEL G, TIMUR S S, BOZKURT I, et al. A Snapshot on the current status of Alzheimer's disease,treatment perspectives,in-vitro and in-vivo research studies and future opportunities[J]. Chem Pharm Bull(Tokyo), 2019, 67(10):1030-1041.doi: 10.1248/cpb.c19-00511.
[2]	VURAL E, HAZAR L, KARAKUKCU C, et al. Apelin-13:A promising biomarker for age-related macular degeneration?[J]. Ophthalmologica, 2021, 244(2):102-109. doi: 10.1159/000513050.
[3]	FULLER K, GRAVLEE C C, MCCARTY C, et al. Stressful social environment and financial strain drive depressive symptoms,and reveal the effects of a FKBP5 variant and male sex,in African Americans living in Tallahassee[J]. Am J Phys Anthropol, 2021, 176(4):572-583. doi: 10.1002/ajpa.24362.
[4]	LOBUONO V, BONANNO I, CORALLO F, et al. Qualitative analysis of minimental state examination Pentagon in vascular dementia and Alzheimer's disease:a longitudinal explorative study[J]. J Stroke Cerebrovasc Dis, 2018, 27(6):1666-1672. doi: 10.1016/j.jstrokecerebrovasdis.2018.01.021.
[5]	PADMANNBHAN P, KNEYNSBERG A, GOTZ J, et al. Super-resolution microscopy:A closer look at synaptic dysfunction in Alzheimer disease[J]. Nat Rev Neurosci, 2021, 22(12):723-740. doi: 10.1038/s41583-021-00531-y.
[6]	陈紫晗, 孙琳琳, 张艺璇, 等. β-淀粉样蛋白清除障碍在阿尔兹海默症发病中的作用[J]. 生理科学进展, 2019, 50(2):149-152.
	CHEN Z H, SUN L L, ZHANG Y X, et al. The roles of amyloid β-protein clearance impairment in the Alzheimer's disease[J]. Progress in Physiological Sciences, 2019, 50(2):149-152. doi: 10.3969/j.issn.0559-7765.2019.02.016.
[7]	ANGELOPOULUO E, PAUDEL Y N, BOUGEA A, et al. Impact of the apelin/APJ axis in the pathogenesis of Parkinson's disease with therapeutic potential[J]. J Neurosci Res, 2021, 99(9):2117-2133. doi: 10.1002/jnr.24895.
[8]	WANG X, TIAN X, PEI L L, et al. The association between serum apelin-13 and the prognosis of acute ischemic stroke[J]. Transl Stroke Res, 2020, 11(4):700-707. doi: 10.1007/s12975-019-00769-w.
[9]	SHAO Z Q, DOU S S, ZHU J G, et al. Apelin-13 inhibits apoptosis and excessive autophagy in cerebral ischemia/reperfusion injury[J]. Neural Regen Res, 2021, 16(6):1044-1051. doi: 10.4103/1673-5374.300725.
[10]	LIU W, NIU F, SHA H, et al. Apelin-13/APJ system delays intervertebral disc degeneration by activating the PI3K/AKT signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2020, 24(6):2820-2828. doi: 10.26355/eurrev_202003_20643.
[11]	WILLI R A, FALTERMANN S, HETTICH T, et al. Active glucocorticoids have a range of important adverse developmental and physiological effects on developing Zebrafish Embryos[J]. Environ Sci Technol, 2018, 52(2):877-885. doi: 10.1021/acs.est.7b06057.
[12]	RICHTER A, AL-BAYATI M, PARASKEVOPOULOU F, et al. Interaction of FKBP5 variant rs3800373 and city living alters the neural stress response in the anterior cingulate cortex[J]. Stress, 2021, 24(4):421-429. doi: 10.1080/10253890.2020.1855420.
[13]	SABBAGH J J, CORDOVA R A, ZHENG D, et al. Targeting the FKBP51/GR/Hsp90 complex to identify functionally relevant treatments for depression and PTSD[J]. ACS Chem Biol, 2018, 13(8):2288-2299. doi: 10.1021/acschembio.8b00454.
[14]	KE X R, FU Q, MAJNIK A, et al. Adverse early life environment induces anxiety-like behavior and increases expression of FKBP5 mRNA splice variants in mouse brain[J]. Physiol Genomics, 2018, 50(11):973-981. doi: 10.1152/physiolgenomics.00054.2018.
[15]	YANG S S, LI H, TANG L, et al. Apelin-13 protects the heart against ischemia-reperfusion injury through the RISK-GSK-3β-mPTP pathway[J]. Arch Med Sci, 2015, 11(5):1065-1073. doi: 10.5114/aoms.2015.54863.
[16]	AMINYAVARI S, ZAHMATKESH M, KHODAGHOLI F, et al. Anxiolytic impact of Apelin-13 in a rat model of Alzheimer's disease:Involvement of glucocorticoid receptor and FKBP5[J]. Peptides, 2019, 18(3):170102-170110. doi: 10.1016/j.peptides.2019.170102.

组别	n	LDL-C （mmol/L）	TC （mmol/L）	Apelin13 （μg/L）	FKBP5 mRNA	MMSE 评分（分）
对照组	90	2.03±0.59	3.78±1.06	43.69±10.06	1.13±0.32	28.29±1.68
AD组	93	2.18±0.63	4.04±1.17	17.82±5.07	3.88±1.11	15.21±4.61
t		1.661	1.574	21.857^＊＊	22.928^＊＊	25.336^＊＊

组别	n	LDL-C （mmol/L）	TC （mmol/L）	Apelin13 （μg/L）	FKBP5 mRNA	MMSE 评分（分）
对照组	90	2.03±0.59	3.78±1.06	43.69±10.06	1.13±0.32	28.29±1.68
AD组	93	2.18±0.63	4.04±1.17	17.82±5.07	3.88±1.11	15.21±4.61
t		1.661	1.574	21.857^＊＊	22.928^＊＊	25.336^＊＊

因素	B	SE	Wald χ²	P	OR（95%CI）
MMSE评分	-0.341	0.142	5.751	0.016	0.711（0.538~0.940）
FKBP5 mRNA	0.791	0.227	12.121	<0.001	2.206（1.413~3.444）
Apelin13	-0.794	0.268	8.802	0.003	0.452（0.267~0.764）
常数项	-0.687	0.263	6.823	<0.001	0.503

因素	B	SE	Wald χ²	P	OR（95%CI）
MMSE评分	-0.341	0.142	5.751	0.016	0.711（0.538~0.940）
FKBP5 mRNA	0.791	0.227	12.121	<0.001	2.206（1.413~3.444）
Apelin13	-0.794	0.268	8.802	0.003	0.452（0.267~0.764）
常数项	-0.687	0.263	6.823	<0.001	0.503

类型	n	Apelin13（μg/L）	FKBP5 mRNA
轻度组	10	25.62±6.91	3.09±0.72
中度组	51	18.92±5.03^a	3.72±0.91^a
重度组	32	13.63±3.27^ab	4.38±0.96^ab
F		27.359^＊＊	9.373^＊＊

阿尔茨海默病患者血清中Apelin13和FKBP5的表达水平及临床意义

The serum expression level and clinical significance of Apelin13 and FKBP5 in patients with Alzheimer's disease

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 5

参考文献 16

相关文章 15

编辑推荐

Metrics

本文评价

因素	AUC（95%CI）	最佳截断值	约登指数	敏感度（%）	特异度（%）
Apelin13	0.776（0.673~0.879）	15.49 μg/L	0.57	78.12	78.69
FKBP5 mRNA	0.801（0.699~0.902）	4.11	0.46	62.50	83.61
Apelin13+FKBP5 mRNA	0.884（0.808~0.961）	-	0.68	81.25	86.89

[1]	焦爱菊, 任宝龙, 张春花, 李文瑞, 赵玮婧. NIHSS评分联合血清BDNF、IL-6对脑卒中后抑郁的预测价值[J]. 天津医药, 2024, 52(9): 963-966.
[2]	李勇, 苏亚坤, 张宏博, 李原, 李占虎, 闫小菊. 原发性高血压早期肾损害患者血清白脂素水平的临床意义[J]. 天津医药, 2024, 52(6): 609-613.
[3]	慕静然, 骆延, 梁璇, 徐陶, 曾俊伟, 刘晓红. 补体系统激活参与阿尔茨海默病的研究进展[J]. 天津医药, 2024, 52(6): 663-668.
[4]	肖雨倩, 孙可心, 万俊, 陈淑颖, 陈丽敏, 王岩, 白艳杰. RNA m6A甲基化在卒中后认知障碍中的研究进展[J]. 天津医药, 2024, 52(3): 331-336.
[5]	孙瑞雪, 刘霄霄, 岳欣怡, 杨冬梅, 任鲁宁, 王菲, 杜红阳. 术前血液学炎症指标对基底细胞癌复发风险的预测价值[J]. 天津医药, 2024, 52(12): 1274-1277.
[6]	顾芸芸, 仲崇明, 杨海燕. 尿酸/白蛋白比值对慢性肾脏病患者并发冠心病的预测价值[J]. 天津医药, 2024, 52(11): 1202-1206.
[7]	吴美娜, 戴为正, 潘毓敦, 傅懋林, 陈晓瑜. 常规脑电图联合血清miR-146a、miR-129-5p水平检测对药物难治性癫痫的临床诊断价值[J]. 天津医药, 2024, 52(11): 1207-1210.
[8]	宫秀娟, 赵慧霞, 张小庆, 张连霞. 重症社区获得性肺炎患者PIV、IL-6、HBP、PAB水平对疗效的评估价值[J]. 天津医药, 2024, 52(11): 1216-1220.
[9]	冉龙飞, 聂志强, 郭军辉. 数字化技术在阿尔茨海默病中的应用进展[J]. 天津医药, 2024, 52(10): 1106-1109.
[10]	王翠, 杨畅, 金玉, 高蜜, 张雯, 王琼, 金海涛. 木犀草苷对阿尔茨海默病模型细胞凋亡和炎性因子表达的研究[J]. 天津医药, 2023, 51(7): 701-706.
[11]	李晓晓, 白艳杰, 王岩, 张雍闯, 陈丽敏, 陈淑颖. 高脂饮食与认知障碍关系的研究进展[J]. 天津医药, 2023, 51(4): 441-444.
[12]	黄晓碧, 赵胜, 郑丽云, 祁晓慧. 急性时相反应蛋白SAA和CRP对川崎病静脉注射免疫球蛋白无应答的预测价值[J]. 天津医药, 2023, 51(3): 299-302.
[13]	滕丽峰, 陈茜茜, 叶丛, 黄玉冰. 血清Sestrin2在急性ST段抬高型心肌梗死中的表达及其与缺血再灌注损伤的关系[J]. 天津医药, 2023, 51(3): 303-306.
[14]	许莉敏, 谢燕. 外周血单核细胞DNMT1及血清IL-6在糖尿病肾脏病中的表达及意义[J]. 天津医药, 2023, 51(2): 194-197.
[15]	陈俊, 郑锦豪, 陈家良, 陈博. 阿尔茨海默病患者血清GGT、CTHRC1表达水平检测及临床意义[J]. 天津医药, 2023, 51(2): 216-220.